Dalbavancin Dosage

Medically reviewed by Drugs.com. Last updated on Sep 23, 2024.

Usual Adult Dose for Skin and Structure Infection

1500 mg IV once as a single infusion OR 1000 mg IV followed 1 week later by 500 mg IV

Use: For the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) due to susceptible strains of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes, S agalactiae, S dysgalactiae, S anginosus group (including S anginosus, S intermedius, S constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates)

Usual Pediatric Dose for Skin and Structure Infection

Birth to less than 6 years: 22.5 mg/kg IV once as a single infusion
6 to less than 18 years: 18 mg/kg IV once as a single infusion
Maximum dose: 1500 mg/dose

Use: For the treatment of patients with ABSSSI due to susceptible strains of the following gram-positive microorganisms: S aureus (including methicillin-susceptible and methicillin-resistant isolates), S pyogenes, S agalactiae, S dysgalactiae, S anginosus group (including S anginosus, S intermedius, S constellatus), and E faecalis (vancomycin-susceptible isolates)

Renal Dose Adjustments

Adult patients:

• CrCl less than 30 mL/min and not receiving regularly scheduled hemodialysis: 1125 mg IV once as a single infusion OR 750 mg IV followed 1 week later by 375 mg IV

Pediatric patients (younger than 18 years):

• CrCl less than 30 mL/min/1.73 m2: Data not available

Comments:

• CrCl or GFR should be estimated using an age-appropriate equation accepted for pediatric patients (birth to less than 18 years) to define renal dysfunction.
• Insufficient information is available to recommend dose adjustment for pediatric patients younger than 18 years with CrCl less than 30 mL/min/1.73 m2.

Liver Dose Adjustments

Mild liver dysfunction (Child-Pugh A): No adjustment recommended.
Moderate to severe liver dysfunction (Child-Pugh B or C): Caution recommended.

Comments:

• No data are available to determine appropriate dosing for patients with moderate or severe liver dysfunction.

Precautions

CONTRAINDICATIONS:
Known hypersensitivity to the active component

Consult WARNINGS section for additional precautions.

Dialysis

Regularly scheduled hemodialysis: No adjustment recommended.
Peritoneal dialysis: Data not available

Comments:

• This drug can be administered without regard to the timing of hemodialysis.

Other Comments

Administration advice:

• Administer by IV infusion over 30 minutes.
• Stopping or slowing the infusion may stop infusion-related reactions.
• Do not co-infuse with other medications or electrolytes.
• If a common IV line is used to administer other drugs in addition to this drug, flush the line with 5% Dextrose Injection, USP before and after each infusion of this drug.

Storage requirements:

• Lyophilized powder: Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F).
• Reconstituted and diluted solutions: May store either refrigerated at 2C to 8C (36F to 46F) or at controlled room temperature 20C to 25C (68F to 77F); do not freeze.
• Total time from reconstitution to dilution to administration should not exceed 48 hours.

Reconstitution/preparation techniques:

• This drug must be reconstituted and then further diluted before administration.
• The manufacturer product information should be consulted.

IV compatibility:

• Compatible: Sterile Water for Injection, USP; 5% Dextrose Injection, USP
• Incompatible: Saline-based infusion solutions may cause precipitation and should not be used.
• The compatibility of the reconstituted solution with IV medications, additives, or substances other than 5% Dextrose Injection, USP has not been established.

General:

• This drug is for the treatment of infections due to susceptible strains of the designated bacteria.
• To reduce the development of drug-resistant organisms and maintain effective therapy, this drug should be used only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria.
• Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.

Patient advice:

• Avoid missing doses and complete the entire course of therapy.
• Consult health care provider if severe watery or bloody diarrhea develops.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer